ARIMIDEX 1MG 28 PILLS — MADE IN UK — FREE SHIPPING

Product description

Arimidex - Highly selective nonsteroidal aromatase inhibitor. Aromatase is an enzyme through which in postmenopausal women, androstenedione in peripheral tissues is converted into estrone and then into estradiol. Reducing circulating estradiol has a therapeutic effect in patients with breast cancer. In postmenopausal medication in a daily dose of 1 mg causes a decrease in estradiol levels by 80%.

Arimidex does not possess progestogenic, androgenic and estrogenic activity.

Arimidex in a daily dose of up to 10 mg has no effect on the secretion of cortisol and aldosterone (therefore, the use of the preparation does not require the replacement of corticosteroids).

Pharmacokinetics

Suction

After oral administration, anastrozole is rapidly absorbed from the gastrointestinal tract. Cmax in plasma is reached within 2 hours (on an empty stomach). Food somewhat reduces the rate, but not the degree of absorption. Small changes in the rate of absorption do not lead to a clinically significant effect on the Css of the preparation in plasma with a daily intake of 1 Arimidex tablet.

Distribution

Anastrozole is associated with plasma proteins by 40%. Approximately 90-95% of Сss is achieved after 7 days of taking the preparation. There is no information about the cumulation of the preparation and the dependence of the pharmacokinetic parameters of anastrozole on time and dose.

Metabolism

Anastrozole is metabolized by N-dealkylation, hydroxylation and glucuronization. Triazole, the major metabolite detected in plasma, does not inhibit aromatase.

Removal

Anastrozole is displayed slowly, T1 / 2 - 40-50 h.

Anastrozole and its metabolites are excreted mainly with urine (less than 10% of the excreted dose - unchanged), within 72 hours after taking the preparation.

Pharmacokinetics in special clinical situations

The determined clearance of anastrozole after oral administration in volunteers with stabilized liver cirrhosis or renal dysfunction does not differ from clearance determined in healthy volunteers.

Anastrozole pharmacokinetics does not depend on age in postmenopausal women.

Indications:

• Adjuvant therapy for early hormone-positive breast cancer in postmenopausal women;
• treatment of advanced breast cancer in postmenopausal women;
• adjuvant therapy for early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2–3 years.

Contraindications

• Renal failure severe (creatinine clearance less than 20 ml / min);
• moderate and severe hepatic impairment (safety and efficacy not established);
• concomitant therapy with tamoxifen;
• children age (safety and efficacy not established
• pregnancy;
• lactation (breastfeeding);
• Hypersensitivity to anastrozole and other components of the preparation.

The preparation is not prescribed to women in premenopausal women.

Suggested Use:

Adults, including elderly patients, the preparation is prescribed 1 mg orally 1 time / day, long-term. If there is evidence of disease progression, the preparation should be discontinued. As adjuvant therapy, the recommended duration of treatment is 5 years.

Patients with mild and moderately severe renal impairment do not require dose adjustment.

Patients with mild hepatic impairment do not require dose adjustment.

The tablet should be swallowed whole and washed down with water. It is recommended to take the preparation at the same time of day.

Packaging:

Comes in original packaging. Item is brand new and unopened.

Storage:

Keep away from direct sunlight.

Keep locked and away from children.

Store in dry place at room temperature.

Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!